Product name
Recombinant Human IGF-BP3 protein
Code
CD01589
Biological activity
Fully biologically active when compared to standard. The ED50 as determined by inhibiting IGF-II induced proliferation of serum free human MCF-7 cells is less than 200 ng/ml, corresponding to a specific activity of > 5.0 × 103 IU/mg in the presence of 15 ng/ml of rHuIGF-II.
Endotoxin
Less than 1 EU/μg of rHuIGF-BP3 as determined by LAL method.
Synonyms
IGF-BP3, IBP3; BP-53,IGFBP3,Human
Sequence
GASSAGLGPVVRCEPCDARALAQCAPPPAVCAELVREPGCGCCLTCALSEGQPCGIYTERCGSGLRCQPSPDEARPLQALLDGRGLCVNASAVSRLRAYLLPAPPAPGNASESEEDRSAGSVESPSVSSTHRVSDPKFHPLHSKIIIIKKGHAKDSQRYKVDYESQSTDTQNFSSESKRETEYGPCRREMEDTLNHLKFLNVLSPRGVHIPNCDKKGFYKKKQCRPSKGRKRGFCWCVDKYGQPLPGYTTKGKEDVHCYSMQSK
Uniprot Accession
Formulation
Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
Background
Insulin-like Growth Factor-Binding Protein 3 (IGF-BP3) belongs to the IGFBP family, which are all cysteinerich proteins with conserved cysteine and have an IGFBP domain and a thyroglobulin type-I domain. Mature human IGF-BP3 contains 264 a.a. with three potential N-linked and two potential O-linked glycosylation sites. It is expressed by most tissues and has higher levels during extrauterine life and peak during puberty. The expression of IGF-BP3 in fibroblasts is stimulated by mitogenic growth factors such as Bombesin, Vasopressin, PDGF, and EGF. The protein forms a ternary complex with IGF-I or II and acid-labile subunit. In this form, it circulates in the plasma, prolonging the half-life of IGFs and altering their interaction with cell surface receptors. Decreased plasma levels of IGF-BP3 often happen during the progression of prostate cancer from benign to metastatic disease.
Storage
-20ºC
Research area
Immunology
